Suppliers / Reyoung Pharmaceutical

Reyoung Pharmaceutical

China 2 duplicate records merged Updated 9 July 2026

The public registers hold a second record for Reyoung Pharmaceutical. The fuller profile, with 9 active US DMFs and 0 valid CEPs, is at Reyoung Pharmaceutical. Figures on this page cover only this record.

Reyoung Pharmaceutical is a finished-dose manufacturer based in China. It appears in 261 regulatory filings across 11 regulators, without an active US DMF or CEP on file. Its filings concentrate with ARCSA (EC), DIGEMAPS (DO) and NAFDAC (NG). Its GMP standing is certified by ANVISA (Brazil), EMA and INVIMA (CO), among 5 authorities.

0
active US DMFs
0
valid CEPs
3
registered plants
261
filings across 11 regulators
These figures were checked against the regulators' own files on 25 July 2026
EU GMP
1 of 1 confirmed
Sources: EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Registered plants

Site FDA FEI
SHANDONG, China Not on file
Zibo, China Not on file
Shandong, Colombia Not on file

Filings and GMP by regulator

Regulator Filings GMP certificates
ARCSA (EC) 78 None
DIGEMAPS (DO) 56 None
NAFDAC (NG) 40 None
MINSA (CR) 31 None
EFDA (ET) 25 None
UZPHARM (UZ) 21 2
ANVISA (Brazil) None 4
EMA None 2
INVIMA (CO) None 2
MFDS (Korea) None 2

Comparing suppliers?

Choose your molecules and target markets. Reyoung Pharmaceutical comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates